https://www.selleckchem.com/EGFR(HER).html Background This review aims to qualitatively summarize the published real-world evidence (RWE) for CDK4/6 inhibitors (CDK4/6i) approved for treating HR+, HER2-negative advanced/metastatic breast cancer (HR+/HER2- a/mBC). Materials & methods A systematic literature review was conducted to identify RWE studies of CDK4/6i in HR+/HER2- a/mBC published from 2015 to 2019. Results This review identified 114 studies, of which 85 were only presented at scientific conferences. Most RWE studies investigated palbociclib and demonstrated improved outcomes. There are limited long-term and comparative data between CDK4/6i and endocrine monotherapy, and within the CDK4/6i class. Conclusion Available RWE suggests that CDK4/6i are associated with improved outcomes in HR+/HER2- a/mBC, although additional studies with longer follow-up periods are needed.Background Because chest compressions induce artifacts in the ECG, current automated external defibrillators instruct the user to stop cardiopulmonary resuscitation (CPR) while an automated rhythm analysis is performed. It has been shown that minimizing interruptions in CPR increases the chance of survival. Methods and Results The objective of this study was to apply a deep-learning algorithm using convolutional layers, residual networks, and bidirectional long short-term memory method to classify shockable versus nonshockable rhythms in the presence and absence of CPR artifact. Forty subjects' data from Physionet with 1131 shockable and 2741 nonshockable samples contaminated with 43 different CPR artifacts that were acquired from a commercial automated external defibrillator during asystole were used. We had separate data as train and test sets. Using our deep neural network model, the sensitivity and specificity of the shock versus no-shock decision for the entire data set over the 4-fold cross-validation sets were 95.21% and 86.03%, respectively. This result was based on the training and tes